AMGEN RESEARCH (MUNICH) GMBH

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
C07K PEPTIDES 5284
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 36219
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 1683
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 8159
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 792
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 544
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 5201
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 3122
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 293
 
  
 
B01D SEPARATION 1133

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0275,373 BISPECIFIC SINGLE CHAIN ANTIBODY CONSTRUCT WITH ENHANCED TISSUE DISTRIBUTIONJul 31, 15Sep 28, 17[C07K]
2017/0218,078 BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTSFeb 02, 17Aug 03, 17[C07K]
2017/0218,079 PSMA and CD3 Bispecific T Cell Engaging Antibody ConstructsFeb 02, 17Aug 03, 17[C07K]
2017/0209,571 PHARMACEUTICAL COMPOSITION COMPRISING BISPECIFIC ANTIBODY CONSTRUCTSJan 25, 17Jul 27, 17[A61K, C07K, B01D]
2017/0129,961 ANTIBODY CONSTRUCTS FOR CD70 AND CD3Aug 01, 16May 11, 17[C07K]
2017/0122,947 RISK-STRATIFICATION OF B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTSMay 20, 15May 04, 17[A61K, G01N, C07K]
2017/0037,133 IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERSAug 05, 16Feb 09, 17[A61K, C07K]
2017/0037,149 ANTIBODY CONSTRUCTS FOR FLT3 AND CD3Aug 01, 16Feb 09, 17[C07K]
2017/0029,502 ANTIBODY CONSTRUCTS FOR MSLN AND CD3Aug 01, 16Feb 02, 17[C07K]
2016/0317,657 COMBINATION OF EPIGENETIC FACTORS AND BISPECIFIC COMPOUNDS TARGETING CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIASep 15, 14Nov 03, 16[A61K, C07K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9919051 Liquid formulation comprising GM-CSF neutralizing compoundOct 31, 13Mar 20, 18[A61K, C07K]
9833410 Lyophilized formulation comprising GM-CSF neutralizing compoundOct 31, 13Dec 05, 17[A61K, C07K]
9765157 Antibody constructs for CDH19 and CD3Jul 31, 15Sep 19, 17[A61K, C07K]
9695250 Pharmaceutical compositions with resistance to soluble CEAJan 14, 13Jul 04, 17[A61K, C07K]
9688760 Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsFeb 08, 14Jun 27, 17[C07H, A61K, A01N, C12P, C12N, C07C, G01N, C07K]
9598500 Binding molecules for BCMA and CD3Nov 15, 12Mar 21, 17[A61K, C12N, C07K]
9587036 Cross-species-specific PSMAxCD3 bispecific single chain antibodyApr 01, 11Mar 07, 17[A61K, C07K]
9505849 Antibody constructs for influenza M2 and CD3Mar 17, 14Nov 29, 16[A61K, C07K]
9486475 PPS for the prevention of potential adverse effects caused by CD3 specific binding domainsFeb 08, 14Nov 08, 16[A61K, A01N]
9340621 Binding molecules for BCMA and CD3Nov 15, 12May 17, 16[A61K, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2014/0242,081 DOSING REGIMENS FOR TREATMENT OF CEA-EXPRESSING CANCERSAbandonedJul 18, 11Aug 28, 14[C07K]
8658172 Treatment of metastatic breast cancerExpiredDec 19, 12Feb 25, 14[A61K]
8337843 Treatment of metastatic breast cancerExpiredJul 11, 11Dec 25, 12[A61K]
2012/0294,873 ANTI-EpCAM IMMUNOGLOBULINSAbandonedJun 01, 12Nov 22, 12[A61K, A61P, C07K]
2012/0244,161 DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODYAbandonedSep 20, 10Sep 27, 12[A61K, A61P]
2012/0244,162 CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERSAbandonedFeb 29, 12Sep 27, 12[A61K, C12P, C12N, A61P, C07K]
7976842 Treatment of metastatic breast cancerExpiredFeb 09, 07Jul 12, 11[A61K]
2009/0241,202 DOMAIN-GRAFTED ANTIBODIESAbandonedDec 14, 06Sep 24, 09[A61K]
2007/0274,982 Anti-EpCam ImmunoglobulinsAbandonedFeb 09, 05Nov 29, 07[A61K, A61P, C07K]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.